Publications:

NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis.

Oncogene

Luiken, Sarah S; Fraas, Angelika A; Bieg, Matthias M; Sugiyanto, Raisatun R; Goeppert, Benjamin B; Singer, Stephan S; Ploeger, Carolin C; Warsow, Gregor G; Marquardt, Jens U JU; Sticht, Carsten C; De La Torre, Carolina C; Pusch, Stefan S; Mehrabi, Arianeb A; Gretz, Norbert N; Schlesner, Matthias M; Eils, Roland R; Schirmacher, Peter P; Longerich, Thomas T; Roessler, Stephanie S

Publication Date: 2020-04

Variant appearance in text: PIK3CA: 1215C>G

PubMed Link: 32055024

Variant Present in the following documents:

• 41388_2020_1198_MOESM2_ESM.xlsx, sheet 1

View BVdb publication page

Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.

Molecular Cancer Therapeutics

Ganesan, Prasanth P; Moulder, Stacy S; Lee, J Jack JJ; Janku, Filip F; Valero, Vicente V; Zinner, Ralph G RG; Naing, Aung A; Fu, Siqing S; Tsimberidou, Apostolia M AM; Hong, David D; Stephen, Bettzy B; Stephens, Philip P; Yelensky, Roman R; Meric-Bernstam, Funda F; Kurzrock, Razelle R; Wheler, Jennifer J JJ

Publication Date: 2014-12

Variant appearance in text: PIK3CA: S405S

PubMed Link: 25253784

Variant Present in the following documents:

• Main text

View BVdb publication page

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

Cell Reports

Janku, Filip F; Hong, David S DS; Fu, Siqing S; Piha-Paul, Sarina A SA; Naing, Aung A; Falchook, Gerald S GS; Tsimberidou, Apostolia M AM; Stepanek, Vanda M VM; Moulder, Stacy L SL; Lee, J Jack JJ; Luthra, Rajyalakshmi R; Zinner, Ralph G RG; Broaddus, Russell R RR; Wheler, Jennifer J JJ; Kurzrock, Razelle R

Publication Date: 2014-01-30

Variant appearance in text: PIK3CA: S405S

PubMed Link: 24440717

Variant Present in the following documents:

• Main text

View BVdb publication page

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.

Molecular Cancer Therapeutics

Ganesan, Prasanth P; Janku, Filip F; Naing, Aung A; Hong, David S DS; Tsimberidou, Apostolia M AM; Falchook, Gerald S GS; Wheler, Jennifer J JJ; Piha-Paul, Sarina A SA; Fu, Siqing S; Stepanek, Vanda M VM; Lee, J Jack JJ; Luthra, Rajyalakshmi R; Overman, Michael J MJ; Kopetz, E Scott ES; Wolff, Robert A RA; Kurzrock, Razelle R

Publication Date: 2013-12

Variant appearance in text: PIK3CA: S405S

PubMed Link: 24092809

Variant Present in the following documents:

• Main text

View BVdb publication page

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Cancer Research

Janku, Filip F; Wheler, Jennifer J JJ; Naing, Aung A; Falchook, Gerald S GS; Hong, David S DS; Stepanek, Vanda M VM; Fu, Siqing S; Piha-Paul, Sarina A SA; Lee, J Jack JJ; Luthra, Rajyalakshmi R; Tsimberidou, Apostolia M AM; Kurzrock, Razelle R

Publication Date: 2013-01-01

Variant appearance in text: PIK3CA: S405S

PubMed Link: 23066039

Variant Present in the following documents:

• Main text

View BVdb publication page